BRPI0815920A2 - Composto, composição farmacêutica, e, uso do composto. - Google Patents

Composto, composição farmacêutica, e, uso do composto.

Info

Publication number
BRPI0815920A2
BRPI0815920A2 BRPI0815920-3A2A BRPI0815920A BRPI0815920A2 BR PI0815920 A2 BRPI0815920 A2 BR PI0815920A2 BR PI0815920 A BRPI0815920 A BR PI0815920A BR PI0815920 A2 BRPI0815920 A2 BR PI0815920A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
iva
formulas
host
Prior art date
Application number
BRPI0815920-3A2A
Other languages
English (en)
Inventor
Cyril Dousson
Dominique Surleraux
Jean-Laurent Paparin
Claire Pierra
Arlene Roland
Original Assignee
Idenix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Pharmaceuticals Inc filed Critical Idenix Pharmaceuticals Inc
Publication of BRPI0815920A2 publication Critical patent/BRPI0815920A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65848—Cyclic amide derivatives of acids of phosphorus, in which two nitrogen atoms belong to the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0815920-3A2A 2007-08-31 2008-08-28 Composto, composição farmacêutica, e, uso do composto. BRPI0815920A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96723707P 2007-08-31 2007-08-31
PCT/US2008/010225 WO2009032180A1 (en) 2007-08-31 2008-08-28 Phosphadiazine hcv polymerase inhibitors iv

Publications (1)

Publication Number Publication Date
BRPI0815920A2 true BRPI0815920A2 (pt) 2015-02-18

Family

ID=39874081

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815920-3A2A BRPI0815920A2 (pt) 2007-08-31 2008-08-28 Composto, composição farmacêutica, e, uso do composto.

Country Status (16)

Country Link
US (4) US20090060866A1 (pt)
EP (1) EP2183260B1 (pt)
JP (1) JP5514108B2 (pt)
KR (1) KR20100072002A (pt)
CN (1) CN101842378A (pt)
AT (1) ATE511514T1 (pt)
AU (1) AU2008296997B2 (pt)
BR (1) BRPI0815920A2 (pt)
CA (1) CA2697546A1 (pt)
ES (1) ES2367550T3 (pt)
MX (1) MX2010002296A (pt)
NZ (1) NZ583545A (pt)
RU (1) RU2483073C2 (pt)
TW (1) TW200927143A (pt)
UA (1) UA95715C2 (pt)
WO (4) WO2009032176A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
EP2389934A1 (en) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
GEP20217282B (en) 2015-03-06 2021-08-10 Atea Pharmaceuticals Inc β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
US10766917B2 (en) 2015-05-27 2020-09-08 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
CN110248951B (zh) 2017-02-01 2022-10-28 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
CN111233925B (zh) * 2018-11-28 2021-03-26 上海日馨生物科技有限公司 硫胺类化合物、制备方法及其药物组合物
EP4081777B1 (en) 2019-12-23 2026-02-18 10X Genomics, Inc. Reversible fixing reagents and methods of use thereof
EP4081656A1 (en) 2019-12-23 2022-11-02 10X Genomics, Inc. Compositions and methods for using fixed biological samples in partition-based assays
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
BR112023026356A2 (pt) 2021-06-17 2024-03-05 Atea Pharmaceuticals Inc Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
CN113698315A (zh) * 2021-09-03 2021-11-26 内蒙古蓝科生物科技有限公司 一种2-三氟甲基苯甲酰胺的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU495317A1 (ru) * 1973-11-14 1975-12-15 Киевский научно-исследовательский институт фармакологии и токсикологии Способ получени этилениминопроизводных 1,2,6-фосфадиазинов
EP1634886A3 (en) 1999-03-05 2006-03-29 Metabasis Therapeutics, Inc. Novel phosphorus-containing prodrug
IL145052A0 (en) * 1999-03-05 2002-06-30 Metabasis Therapeutics Inc Novel phosphorus-containing prodrugs
AU4329000A (en) * 1999-04-19 2000-11-02 G.D. Searle & Co. Novel heterocyclic amino carbonyl derivatives useful as nitric oxide synthase inhibitors
WO2003099801A1 (en) * 2002-05-24 2003-12-04 Smithkline Beecham Corporation Novel anti-infectives
RU2007110531A (ru) * 2004-08-23 2008-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические противовирусные соединения
CN101384587B (zh) * 2006-02-17 2011-03-30 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物

Also Published As

Publication number Publication date
RU2010112408A (ru) 2011-10-10
US7932240B2 (en) 2011-04-26
CA2697546A1 (en) 2009-03-12
CN101842378A (zh) 2010-09-22
EP2183260A1 (en) 2010-05-12
WO2009032177A1 (en) 2009-03-12
WO2009032179A1 (en) 2009-03-12
EP2183260B1 (en) 2011-06-01
NZ583545A (en) 2011-04-29
US20090081158A1 (en) 2009-03-26
ATE511514T1 (de) 2011-06-15
RU2483073C2 (ru) 2013-05-27
JP5514108B2 (ja) 2014-06-04
AU2008296997B2 (en) 2013-08-29
US20090060866A1 (en) 2009-03-05
KR20100072002A (ko) 2010-06-29
AU2008296997A1 (en) 2009-03-12
UA95715C2 (ru) 2011-08-25
HK1137028A1 (en) 2010-07-16
ES2367550T3 (es) 2011-11-04
WO2009032180A1 (en) 2009-03-12
US20090060867A1 (en) 2009-03-05
JP2010537986A (ja) 2010-12-09
MX2010002296A (es) 2010-04-01
WO2009032176A1 (en) 2009-03-12
US20090060872A1 (en) 2009-03-05
TW200927143A (en) 2009-07-01

Similar Documents

Publication Publication Date Title
ATE511514T1 (de) Phosphadiazin-hcv-polymerase-hemmer vom typ iv
ECSP10010413A (es) Inhibidores macrociclicos de serina proteasa
UY30759A1 (es) Compuestos quimicos
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CY1110813T1 (el) Χημικες ενωσεις
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
NO20090628L (no) Pyridizinon derivativater
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
ATE523487T1 (de) 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
WO2010101967A3 (en) Phosphothiophene and phosphothiazole hcv polymerase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]